Figure 1 (Tecentriq 01)
Tecentriq Hybreza Injection
Product Images NDC 50242-933
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tecentriq Hybreza (NDC 50242-933). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Tecentriq 02)
This data appears to be related to a survival analysis study where the number of individuals at risk over time is recorded. The table shows the number of individuals at risk for each time point in months, along with a group that received chemotherapy. This information can be used to analyze the survival rates and outcomes of individuals undergoing chemotherapy compared to those who did not.*
Figure 3 (Tecentriq 03)
Figure 4 (Tecentriq 04)
This is a data table showing the probability of survival for different treatment options over a period of months. The data includes the number of participants at risk and the time in months, with differences in survival rates observed between treatments such as intravenous atezolizumab with pociase protein-bound and carboplatin, as well as pacitaxel protein-bound with carboplatin. The information suggests a comparison of survival outcomes based on the treatments administered.*
Figure 5 (Tecentriq 05)
Figure 6 (Tecentriq 06)
Figure 7 (Tecentriq 07)
This is a table showing the probability of overall survival for patients receiving the combination treatment of intravenous atezolizumab + bevacizumab with Sorafenib over a period of 17 months. The data includes percentages of survival at different time points, ranging from 1 to 17 months. This information can be helpful for evaluating the efficacy and potential outcomes of these treatment options for patients.*
Figure 8 (Tecentriq 08)
This is a table displaying the number of patients remaining at risk over time (in months) for two different treatments: Intravenous atezolizumab and cobimetinib + vemurafenib. The data also includes the percentage of patients at each timepoint.*
Principal Display Panel (15 mL Vial Box)
This text provides information about a medication called Tecentriq Hybreza which is an injection with the active ingredients atezolizumab and hyaluronidase-tgjs, intended for subcutaneous use. The NDC code is 50242-933-01, and it is in a single-dose vial format. It emphasizes discarding any unused portion and advises pharmacists to give the accompanying medication guide to each patient.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
